Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells

European Journal of Nuclear Medicine

Volumn 29, Issue 12, 2002, Pages 1669-1674

  Li, Xiao Feng ^a   Kinuya, Seigo ^a   Yokoyama, Kunihiko ^a   Koshida, Kiyoshi ^a   Mori, Hirofumi ^b   Shiba, Kazuhiro ^b   Watanabe, Naoto ^c   Shuke, Noriyuki ^d   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

2 Methoxyestradiol; Anti angiogenic therapy; Metastasis model; Radioimmunotherapy

Indexed keywords

2 METHOXYESTRADIOL; MONOCLONAL ANTIBODY A7 I 131; MONOCLONAL ANTIBODY I 131; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; INOCULATION; LIVER METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; ANIMAL; ANTIBODY SPECIFICITY; BODY BURDEN; CANCER TRANSPLANTATION; COLON TUMOR; COMPARATIVE STUDY; EVALUATION; FEMALE; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; ANIMAL EXPERIMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BODY BURDEN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 1842847331     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0997-9     Document Type: Article

References (27)

1. Imam SK. Status of radioimmunotherapy in the new millennium. Cancer Biother Radiopharm 2001; 16:237-256.
2. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991; 83:627-632.
3. 131I-labeled monoclonal antibodies. Cancer Res 1992; 52:6036-6044.
4. Dunn RM, Juweid M, Sharkey RM, Behr TM, Goldenberg DM. Can occult metastases be treated by radioimmunotherapy? Cancer (Suppl) 1997; 80:2656-2659.
5. Vogel C-A, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997; 57:447-453.
6. Behr TM, Blumenthal RD, Memtsoudis S, et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 2000; 6:4900-4907.
7. Saga T, Sakahara H, Nakamoto Y, et al. Radioimmunotherapy for liver micrometastases in mice: Pharmacokinetics, dose estimation, and long-term effect. Jpn J Cancer Res 1999; 90: 342-348.
8. Sato N, Saga T, Sakahara H, et al. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J Nucl Med 1999; 40:685-692.
9. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68:403-406.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1:27-31.
11. Kinuya S, Kawashima A, Yokoyama K, et al. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med 2001; 28:1306-1312.
12. Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and anti-angiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med 2002; 43:1084-1089.
13. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
14. Mukhopadhyay T, Roth JA. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 1998; 17:241-246.
15. Tsukamoto A, Kaneko Y, Yoshida T, Han K, Ichinose M, Kimura S. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun 1998; 248:9-12.
16. Reiser F, Way D, Bernas M, Witte M, Witte C. Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med 1998; 219:211-216.
17. Kotanagi H, Takahashi T, Masuko T, Hashimoto Y, Koyama K. A monoclonal antibody against human colon cancers. Tohoku J Exp Med 1986; 148:353-360.
18. Hirano K, Iiizumi Y, Hayashi Y, et al. A highly sensitive assay method for human placental alkaline phosphatase involving a monoclonal antibody bound to a paper disk. Anal Biochem 1986; 154:624-631.
19. 186Re-labeled monoclonal antibody to treat liver metastases of colon cancer cells in nude mice. Cancer Biother Radiopharm 2002; in press.
20. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicines site. Proc Natl Acad Sci U S A 1994; 91:3964-3968.
21. Hamel E, Lin CM, Fglynn E, D'amato RJ. Interaction of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 1996; 35:1304-1310.
22. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
23. Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: Effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986; 27:422-427.
24. Behr TM, Shrkey RM, Juweid M, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997; 38:409-419.
25. 2H nuclear magnetic resonance studies. Cancer Res 1991; 51:3289-3295.
26. Hall EJ. Radiobiology for the Radiologist, 5th Edn. Philadelphia: Lippincott Williams and Wilkins, 2000.
27. MacKillop WJ, Ciampi A, Till JE, Buick RN. A stem cell model of human tumor growth: Implications for tumor cell clonogenic assays. J Natl Cancer Inst 1983; 70:9-16.